Paul D. Andrews
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul D. Andrews has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Jason R. Swedlow
Division of Molecular Cell and Developmental Biology, School of Life Sciences, University of Dundee
11 shared publications - Michael J. R. Stark
Centre for Gene Regulation & Expression, College of Life Sciences, MSI/WTB Complex, University of Dundee, Dundee DD1 5EH, Scotland, UK
6 shared publications - Christopher Lowther Robert Barratt
University of Dundee
2 shared publications Jane Gilmour
Faculty of Biological and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, U.K.
2 shared publicationsMelissa Becroft
Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, U.K.
2 shared publications- Melpomeni Platani
Division of Molecular Cell and Developmental Biology, School of Life Sciences, University of Dundee
2 shared publications
Latest Publications
- 9 December 2020
- Published by Royal Society of Chemistry (RSC)
- p. 118-139
Public–Private Partnerships to Advance Phenotypic Drug Discovery
In this chapter, we discuss the rise and rationale for public–private partnerships (PPP) in phenotypic drug discovery (PDD) from both the academic and industrial perspectives. We then give a review of the three most common “precompetitive” PPP in PDD formats, namely collaborative, co-localized and industry-supported, before finally providing an outlook/conclusion, highlighting the factors we feel contribute to successful PDD partnerships, and the directions we feel these partnerships could take to improve outcomes for both partners.
- 9 December 2020
- Published by Royal Society of Chemistry (RSC)
- p. 118-139
Public–Private Partnerships to Advance Phenotypic Drug Discovery
In this chapter, we discuss the rise and rationale for public–private partnerships (PPP) in phenotypic drug discovery (PDD) from both the academic and industrial perspectives. We then give a review of the three most common “precompetitive” PPP in PDD formats, namely collaborative, co-localized and industry-supported, before finally providing an outlook/conclusion, highlighting the factors we feel contribute to successful PDD partnerships, and the directions we feel these partnerships could take to improve outcomes for both partners.
- Open Access
- 28 January 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
A phenotypic screening platform utilising human spermatozoa identifies compounds with contraceptive activity
There is an urgent need to develop new methods for male contraception, however a major barrier to drug discovery has been the lack of validated targets and the absence of an effective high-throughput phenotypic screening system. To address this deficit, we developed a fully-automated robotic screening platform that provided quantitative evaluation of compound activity against two key attributes of human sperm function: motility and acrosome reaction. In order to accelerate contraceptive development, we screened the comprehensive collection of 12,000 molecules that make up the ReFRAME repurposing library, comprising nearly all the small molecules that have been approved or have undergone clinical development, or have significant preclinical profiling. We identified several compounds that potently inhibit motility representing either novel drug candidates or routes to target identification. This platform will now allow for major drug discovery programmes that address the critical gap in the contraceptive portfolio as well as uncover novel human sperm biology.
- 28 January 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
Open AccessA phenotypic screening platform utilising human spermatozoa identifies compounds with contraceptive activity
There is an urgent need to develop new methods for male contraception, however a major barrier to drug discovery has been the lack of validated targets and the absence of an effective high-throughput phenotypic screening system. To address this deficit, we developed a fully-automated robotic screening platform that provided quantitative evaluation of compound activity against two key attributes of human sperm function: motility and acrosome reaction. In order to accelerate contraceptive development, we screened the comprehensive collection of 12,000 molecules that make up the ReFRAME repurposing library, comprising nearly all the small molecules that have been approved or have undergone clinical development, or have significant preclinical profiling. We identified several compounds that potently inhibit motility representing either novel drug candidates or routes to target identification. This platform will now allow for major drug discovery programmes that address the critical gap in the contraceptive portfolio as well as uncover novel human sperm biology.
- Open Access
A phenotypic screening platform utilising human spermatozoa identifies new compounds with contraceptive activity
There is an urgent need to develop new methods for male contraception, however a major barrier to drug discovery has been the lack of validated targets and the absence of an effective high-throughput phenotypic screening system. To address this deficit, we developed a fully-automated robotic screening platform that provided quantitative evaluation of compound activity against two key attributes of human sperm function: motility and acrosome reaction. In order to accelerate contraceptive development, we screened the comprehensive collection of 12,000 molecules that make up the ReFRAME repurposing library, comprising nearly all the small molecules that have been approved or have undergone clinical development, or have significant preclinical profiling. We identified several compounds that potently inhibit motility representing either novel drug candidates or routes to target identification. This platform will now allow for major drug discovery programmes that address the critical gap in the contraceptive portfolio as well as uncover novel human sperm biology.
Open AccessA phenotypic screening platform utilising human spermatozoa identifies new compounds with contraceptive activity
There is an urgent need to develop new methods for male contraception, however a major barrier to drug discovery has been the lack of validated targets and the absence of an effective high-throughput phenotypic screening system. To address this deficit, we developed a fully-automated robotic screening platform that provided quantitative evaluation of compound activity against two key attributes of human sperm function: motility and acrosome reaction. In order to accelerate contraceptive development, we screened the comprehensive collection of 12,000 molecules that make up the ReFRAME repurposing library, comprising nearly all the small molecules that have been approved or have undergone clinical development, or have significant preclinical profiling. We identified several compounds that potently inhibit motility representing either novel drug candidates or routes to target identification. This platform will now allow for major drug discovery programmes that address the critical gap in the contraceptive portfolio as well as uncover novel human sperm biology.
- 1 September 2011
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 3 (12) , 1539-1549
Discovering Small Molecules to Control Stem Cell Fate
Pluripotent stem cells promise to revolutionize drug discovery and offer new modes of therapy. The ease with which they can be grown in bulk and their differentiation controlled in vitro is of importance for their widespread adoption by industry and their clinical efficacy. Small molecules have already had a positive impact on several areas of stem cell biology, from maintenance of pluripotency, the promotion of single cell survival and steering differentiation to involvement in reprogramming somatic cells. High-throughput technology has played an important role in identifying novel compounds, however to date there are few published examples of medicinal chemistry input in this area. This review discusses the potential of pluripotent stem cells, the successful uses of small molecules and future prospects.
- 1 September 2011
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 3 (12) , 1539-1549
Discovering Small Molecules to Control Stem Cell Fate
Pluripotent stem cells promise to revolutionize drug discovery and offer new modes of therapy. The ease with which they can be grown in bulk and their differentiation controlled in vitro is of importance for their widespread adoption by industry and their clinical efficacy. Small molecules have already had a positive impact on several areas of stem cell biology, from maintenance of pluripotency, the promotion of single cell survival and steering differentiation to involvement in reprogramming somatic cells. High-throughput technology has played an important role in identifying novel compounds, however to date there are few published examples of medicinal chemistry input in this area. This review discusses the potential of pluripotent stem cells, the successful uses of small molecules and future prospects.
- 25 October 2010
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 432 (1) , 21-35
High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules
The propensity of human embryonic stem cells to die upon enzymatic disaggregation or low-density plating is an obstacle to their isolation and routine use in drug discovery and basic research. Equally, the very low rate of establishment of implanted cells hinders cell therapy. In the present study we have developed a high-content assay for human embryonic stem cell survival and used this to screen a range of libraries of ‘lead-like’ small molecules and known bioactives. From this we identified 18 confirmed hits with four structural classes being represented by multiple compounds: a series of 5-(acyl/alkyl-amino)indazoles, compounds with a 4-(acylamino)pyridine core, simple N6,N6-dialkyladenines and compounds with a 5-(acylamino)indolinone core. In vitro kinase profiling indicated that the ROCK (Rho-associated kinase)/PRK2 (protein kinase C-related kinase 2) protein kinases are of pivotal importance for cell survival and identified previously unreported compound classes that inhibited this important biological activity. An evaluation using an extensive panel of protein kinases showed that six of our hit compounds exhibited better selectivity for ROCK inhibition than the routinely used commercially available ROCK inhibitor Y-27632. In this screen we also identified the K+-ATP channel opener pinacidil and show that it probably promotes cell survival, by ‘off-target’ inhibition of ROCK/PRK2. We have therefore identified novel pro-survival compounds of greater specificity, equivalent potency and reduced toxicity relative to the routinely employed ROCK inhibitor Y-27632.
- 25 October 2010
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 432 (1) , 21-35
High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules
The propensity of human embryonic stem cells to die upon enzymatic disaggregation or low-density plating is an obstacle to their isolation and routine use in drug discovery and basic research. Equally, the very low rate of establishment of implanted cells hinders cell therapy. In the present study we have developed a high-content assay for human embryonic stem cell survival and used this to screen a range of libraries of ‘lead-like’ small molecules and known bioactives. From this we identified 18 confirmed hits with four structural classes being represented by multiple compounds: a series of 5-(acyl/alkyl-amino)indazoles, compounds with a 4-(acylamino)pyridine core, simple N6,N6-dialkyladenines and compounds with a 5-(acylamino)indolinone core. In vitro kinase profiling indicated that the ROCK (Rho-associated kinase)/PRK2 (protein kinase C-related kinase 2) protein kinases are of pivotal importance for cell survival and identified previously unreported compound classes that inhibited this important biological activity. An evaluation using an extensive panel of protein kinases showed that six of our hit compounds exhibited better selectivity for ROCK inhibition than the routinely used commercially available ROCK inhibitor Y-27632. In this screen we also identified the K+-ATP channel opener pinacidil and show that it probably promotes cell survival, by ‘off-target’ inhibition of ROCK/PRK2. We have therefore identified novel pro-survival compounds of greater specificity, equivalent potency and reduced toxicity relative to the routinely employed ROCK inhibitor Y-27632.
- Open Access
- 1 September 2009
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Protocols
- Vol. 2009 (9) , pdb.ip70-.70
In Vivo Imaging of Mammalian Cells: Image Acquisition and Analysis: Figure 1.
Live cell imaging provides a powerful technique for the analysis of molecular dynamics within cells. Advances in imaging technology and probe design have established this approach as an important tool in modern biology. It is now possible to obtain commercial turnkey systems for digital imaging using a number of different imaging modalities. Nevertheless, it still requires considerable technical care and expertise to conduct a successful experiment. To perform a successful imaging experiment, it is important to maximize the signal-to-noise ratio (S:N) while minimizing damage to the cells. In this article, we focus on the use of fluorescence microscopy in live cell imaging, although most of the points discussed are relevant to any type of imaging. We describe many of the methods and considerations that are required for performing a successful imaging experiment in living cells. However, we do not provide a single recipe for success: The approach is much too empirical and depends on careful observation of the particular cells under investigation.
- 1 September 2009
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Protocols
- Vol. 2009 (9) , pdb.ip70-.70
Open AccessIn Vivo Imaging of Mammalian Cells: Image Acquisition and Analysis: Figure 1.
Live cell imaging provides a powerful technique for the analysis of molecular dynamics within cells. Advances in imaging technology and probe design have established this approach as an important tool in modern biology. It is now possible to obtain commercial turnkey systems for digital imaging using a number of different imaging modalities. Nevertheless, it still requires considerable technical care and expertise to conduct a successful experiment. To perform a successful imaging experiment, it is important to maximize the signal-to-noise ratio (S:N) while minimizing damage to the cells. In this article, we focus on the use of fluorescence microscopy in live cell imaging, although most of the points discussed are relevant to any type of imaging. We describe many of the methods and considerations that are required for performing a successful imaging experiment in living cells. However, we do not provide a single recipe for success: The approach is much too empirical and depends on careful observation of the particular cells under investigation.
- Open Access
- 1 September 2009
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Protocols
- Vol. 2009 (9) , pdb.ip69-.69
In Vivo Imaging of Mammalian Cells: Cell Engineering and Viability
INTRODUCTION: There are a number of instances in which the use of live cell imaging has provided critical insight into cellular and tissue function. It has therefore become a requisite analytical tool for use in cell biology, neurobiology, and developmental biology, as well as a routine method practiced in many biomedical research laboratories. The technical requirements for performing live cell imaging include a capacity to engineer appropriate cells for the imaging experiment and access to a digital image acquisition system. The availability of fluorescent protein (FP) technology allows the molecular specificity of fluorescent markers to be used in a genetically encoded manner. In this article, we describe techniques for the generation and maintenance of fluorescently labeled cells and their use in live cell imaging experiments.
- 1 September 2009
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Protocols
- Vol. 2009 (9) , pdb.ip69-.69
Open AccessIn Vivo Imaging of Mammalian Cells: Cell Engineering and Viability
INTRODUCTION: There are a number of instances in which the use of live cell imaging has provided critical insight into cellular and tissue function. It has therefore become a requisite analytical tool for use in cell biology, neurobiology, and developmental biology, as well as a routine method practiced in many biomedical research laboratories. The technical requirements for performing live cell imaging include a capacity to engineer appropriate cells for the imaging experiment and access to a digital image acquisition system. The availability of fluorescent protein (FP) technology allows the molecular specificity of fluorescent markers to be used in a genetically encoded manner. In this article, we describe techniques for the generation and maintenance of fluorescently labeled cells and their use in live cell imaging experiments.
- 31 August 2009
- Published by Elsevier in Mechanisms of Development
- Vol. 126, S271-S272
17-P003 Discovery of small molecules to control human embryonic stem cell fate
- 31 August 2009
- Published by Elsevier in Mechanisms of Development
- Vol. 126, S271-S272
17-P003 Discovery of small molecules to control human embryonic stem cell fate
- 15 May 2007
- Published by Taylor & Francis in Cell Cycle
- Vol. 6 (10) , 1220-1230
Phosphorylation by Aurora-B Negatively Regulates Survivin Function During Mitosis
Survivin operates in a complex with aurora B kinase and is phosphorylated by it on threonine 117 in vitro. Here we ask whether phosphorylation of survivin by aurora B kinase regulates its function during mitosis in vivo. Using a phospho-specific antibody we first establish that survivin is phosphorylated at T117 during mitosis and is present at the midbody during cytokinesis. Next we use two independent RNAi complementation approaches to investigate threonine 117 mutants in survivin depleted cells. Our data suggest that while non-phosphorylatable survivin, survivinT117A, can substitute for the wild type protein, a phosphomimic, survivinT117E cannot restore viability, nor can it complement chromosome congression and spindle checkpoint defects that arise due to depletion of endogenous survivin. Fluorescence imaging and fluorescence recovery after photobleaching analysis suggest that the phosphomimic has reduced affinity for centromeres compared with the non-phosphorylatable form. We conclude that survivin i...
- 15 May 2007
- Published by Taylor & Francis in Cell Cycle
- Vol. 6 (10) , 1220-1230
Phosphorylation by Aurora-B Negatively Regulates Survivin Function During Mitosis
Survivin operates in a complex with aurora B kinase and is phosphorylated by it on threonine 117 in vitro. Here we ask whether phosphorylation of survivin by aurora B kinase regulates its function during mitosis in vivo. Using a phospho-specific antibody we first establish that survivin is phosphorylated at T117 during mitosis and is present at the midbody during cytokinesis. Next we use two independent RNAi complementation approaches to investigate threonine 117 mutants in survivin depleted cells. Our data suggest that while non-phosphorylatable survivin, survivinT117A, can substitute for the wild type protein, a phosphomimic, survivinT117E cannot restore viability, nor can it complement chromosome congression and spindle checkpoint defects that arise due to depletion of endogenous survivin. Fluorescence imaging and fluorescence recovery after photobleaching analysis suggest that the phosphomimic has reduced affinity for centromeres compared with the non-phosphorylatable form. We conclude that survivin i...
- 28 July 2005
- Published by Springer Nature in Oncogene
- Vol. 24 (32) , 5005-5015
Aurora kinases: shining lights on the therapeutic horizon?
The Aurora kinases have been implicated in tumorigenesis and are important regulators of diverse cell cycle events, ranging from the entry into mitosis, centrosome function, mitotic spindle formation, chromosome biorientation and segregation, and cytokinesis. The recent identification of novel binding partners and key downstream effectors, together with new small-molecule inhibitors that display efficacy against tumours, heralds an upsurge of interest in these critical kinases. This review details new developments in the field and analyses the potential of Aurora kinases as anticancer targets.
- 28 July 2005
- Published by Springer Nature in Oncogene
- Vol. 24 (32) , 5005-5015
Aurora kinases: shining lights on the therapeutic horizon?
The Aurora kinases have been implicated in tumorigenesis and are important regulators of diverse cell cycle events, ranging from the entry into mitosis, centrosome function, mitotic spindle formation, chromosome biorientation and segregation, and cytokinesis. The recent identification of novel binding partners and key downstream effectors, together with new small-molecule inhibitors that display efficacy against tumours, heralds an upsurge of interest in these critical kinases. This review details new developments in the field and analyses the potential of Aurora kinases as anticancer targets.